-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the help of AI pharmaceuticals, it can improve the speed of new drug research and development and reduce costs, and help pharmaceutical companies to speed up innovation and transformation, reduce costs and increase efficien.
Therefore, with the continuous development of AI technology in recent years, in order to accelerate the research and development of new drugs , Pharmaceutical companies have begun to move frequently in the field of AI, especially in cooperation with technology companies, there is continuous ne.
Recently, Yunnan Baiyao announced that it has signed a comprehensive cooperation agreement with Huawei to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, including large and small molecule design, related diseases, database development,e.
It is understood that Yunnan Baiyao has stated in public earlier that the company will focus on the "1+4+1" strategy to do a good job in corporate transformation and developme.
Among them, in terms of digital technology, Yunnan Baiyao said that it will introduce new technologies, including artificial intelligence, into all aspects of R&D and operation, so that the development has a higher starting poi.
Before the signing of this cooperation agreement, Baiyunshan had already "captured" two Huawei genera.
After Dong Ming, the former vice president of Huawei Technologies .
, L.
China, joined Yunnan Baiyao as the company's CEO in March 2021; Ma Jia, the former CFO of Huawei Technologies .
, L.
China, has also joined Yunnan Baiyao as the C.
On January 11 this year, Shanghai Fosun Pharma and Insilico Medicine, an end-to-end artificial intelligence-driven drug development company, also jointly announced a cooperation agreement to jointly promote the development of AI drugs for multiple targets global.
This collaboration will combine Insilico's end-to-end AI-driven drug discovery platform with Fosun Pharma's strong clinical development and commercial promotion capabilities to discover and develop a combination of innovative drugs and therapi.
In the same month, Sanofi and Exscientia, a British drug research and development AI technology service provider, also reached a huge AI pharmaceutical order worth 31 billion yu.
Under the partnership, Exscientia will be eligible to receive high-single-digit to mid-teens sales share, which can be increased to 21%, if Sanofi commercializes the co-produ.
In addition to the above pharmaceutical companies, a large number of pharmaceutical companies have accelerated the deployment of AI drug research and development, such as Fermion Technology, Xingkang Biotechnology, Yudao Biology, Deep Knowledge Analytics, Recursion Pharmaceuticals, Benevole.
Al, Exscientia,e.
Industry insiders believe that AI technology can deeply participate in the research and development of new drugs, promote the discovery of new biological target mechanisms and the development of new disease treatment mode.
Therefore, in the future, the layout of pharmaceutical companies in AI will be more frequent, and more new achievements will be ushered .
In fact, under the continuous increase, the current layout of pharmaceutical companies has begun to usher in new breakthroug.
At the beginning of April this year, Jingtai Technology announced that it has made important progress in the cooperation with Chia Tai Tianqing in the cooperation of difficult new anti-tumor dru.
With the help of the intelligent and automated drug discovery platform, it took only 50% of the original plan to achieve .
Significant milestones, significantly reducing development ti.
In addition, Xingyao Technology also announced that its self-developed artificial intelligence drug discovery platform Pyxir has identified a new type of preclinical candidate compound (PCC) for the treatment of autoimmune diseases, which verifies its AI-centric, technology-driven Closing the loop for drug discovery capabiliti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Therefore, with the continuous development of AI technology in recent years, in order to accelerate the research and development of new drugs , Pharmaceutical companies have begun to move frequently in the field of AI, especially in cooperation with technology companies, there is continuous ne.
Recently, Yunnan Baiyao announced that it has signed a comprehensive cooperation agreement with Huawei to carry out extensive exchanges and cooperation in the field of artificial intelligence drug research and development, including large and small molecule design, related diseases, database development,e.
It is understood that Yunnan Baiyao has stated in public earlier that the company will focus on the "1+4+1" strategy to do a good job in corporate transformation and developme.
Among them, in terms of digital technology, Yunnan Baiyao said that it will introduce new technologies, including artificial intelligence, into all aspects of R&D and operation, so that the development has a higher starting poi.
Before the signing of this cooperation agreement, Baiyunshan had already "captured" two Huawei genera.
After Dong Ming, the former vice president of Huawei Technologies .
, L.
China, joined Yunnan Baiyao as the company's CEO in March 2021; Ma Jia, the former CFO of Huawei Technologies .
, L.
China, has also joined Yunnan Baiyao as the C.
On January 11 this year, Shanghai Fosun Pharma and Insilico Medicine, an end-to-end artificial intelligence-driven drug development company, also jointly announced a cooperation agreement to jointly promote the development of AI drugs for multiple targets global.
This collaboration will combine Insilico's end-to-end AI-driven drug discovery platform with Fosun Pharma's strong clinical development and commercial promotion capabilities to discover and develop a combination of innovative drugs and therapi.
In the same month, Sanofi and Exscientia, a British drug research and development AI technology service provider, also reached a huge AI pharmaceutical order worth 31 billion yu.
Under the partnership, Exscientia will be eligible to receive high-single-digit to mid-teens sales share, which can be increased to 21%, if Sanofi commercializes the co-produ.
In addition to the above pharmaceutical companies, a large number of pharmaceutical companies have accelerated the deployment of AI drug research and development, such as Fermion Technology, Xingkang Biotechnology, Yudao Biology, Deep Knowledge Analytics, Recursion Pharmaceuticals, Benevole.
Al, Exscientia,e.
Industry insiders believe that AI technology can deeply participate in the research and development of new drugs, promote the discovery of new biological target mechanisms and the development of new disease treatment mode.
Therefore, in the future, the layout of pharmaceutical companies in AI will be more frequent, and more new achievements will be ushered .
In fact, under the continuous increase, the current layout of pharmaceutical companies has begun to usher in new breakthroug.
At the beginning of April this year, Jingtai Technology announced that it has made important progress in the cooperation with Chia Tai Tianqing in the cooperation of difficult new anti-tumor dru.
With the help of the intelligent and automated drug discovery platform, it took only 50% of the original plan to achieve .
Significant milestones, significantly reducing development ti.
In addition, Xingyao Technology also announced that its self-developed artificial intelligence drug discovery platform Pyxir has identified a new type of preclinical candidate compound (PCC) for the treatment of autoimmune diseases, which verifies its AI-centric, technology-driven Closing the loop for drug discovery capabiliti.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
